Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/169408
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huguet, Josep Ma. | - |
dc.contributor.author | Olivan Riera, Mireia | - |
dc.contributor.author | Busquets Rius, Sílvia | - |
dc.contributor.author | López-Soriano, Francisco J. | - |
dc.date.accessioned | 2020-07-23T10:26:08Z | - |
dc.date.available | 2020-07-23T10:26:08Z | - |
dc.date.issued | 2010-01-22 | - |
dc.identifier.issn | 1179-1322 | - |
dc.identifier.uri | http://hdl.handle.net/2445/169408 | - |
dc.description.abstract | According to a recent consensus, cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the majority of cancer patients before death and it is responsible for the deaths of 22% of cancer patients. Although bodyweight is the most important endpoint of any cachexia treatment, body composition, physical performance and quality of life should be monitored. From the results presented here, one can speculate that a single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful. The objectives of any therapeutic combination are two-fold: an anticatabolic aim directed towards both fat and muscle catabolism and an anabolic objective leading to the synthesis of macromolecules such as contractile proteins. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/cmar.s7101 | - |
dc.relation.ispartof | Cancer Management and Research, 2010, vol. 2, p. 27-38 | - |
dc.relation.uri | https://doi.org/10.2147/cmar.s7101 | - |
dc.rights | cc-by-nc (c) Huguet, Josep Ma. et al., 2010 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Anorèxia nerviosa | - |
dc.subject.classification | Càncer | - |
dc.subject.classification | Medicaments | - |
dc.subject.other | Anorexia nervosa | - |
dc.subject.other | Cancer | - |
dc.subject.other | Drugs | - |
dc.title | Optimal management of cancer cachexia-anorexia syndrome | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 584062 | - |
dc.date.updated | 2020-07-23T10:26:09Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 21188094 | - |
Appears in Collections: | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) Articles publicats en revistes (Patologia i Terapèutica Experimental) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
584062.pdf | 225.87 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License